AtaGenix's BEVS platform (Sf9/Sf21/Hi5) delivers properly folded, glycosylated recombinant proteins from milligram to gram scale. Four peer-reviewed publications showcase BEVS-produced reagents in oncology (Nat Commun, POLD1-MYC), tumor immunology (Biomed Pharmacother, PADI4 mAb), neuroscience (Nat Commun, PCIF1-MTase), and gynecological oncology (AJCR, ENO1 mAb). ISO 9001 & ISO 13485 certified.

AtaGenix's 3H E. coli expression platform (>95% success rate) delivers publication-grade recombinant proteins from mg to gram scale. Optimized vectors (pET/pGEX), specialized strains (T7E, C41, Arctic), and full QC (purity ≥85%, endotoxin <0.1 EU/mL). Three peer-reviewed case studies — all in Nature Communications — showcase E. coli-expressed reagents for rice genetics (SDR3.1), Bt resistance (FTZ-F1), and cyanobacterial stress tolerance (shikimate kinase).

AtaGenix's mammalian expression platform (HEK293/CHO-S transient, CHO-K1/DG44 stable) has delivered 5,000+ projects with 200+ stable cell lines. Four peer-reviewed publications showcase mammalian-expressed reagents: OMV tumor vaccine (Adv Mater IF 27.4), SARS-CoV-2 nanovaccine (Nat Commun IF 14.7), EAE neuroinflammation (Immunity IF 25.5), and PND complement inhibition (Mol Psychiatry IF 9.6). Class 100,000 cleanroom, endotoxin <0.1 EU/mL, ISO certified.

Using high-purity recombinant mouse MOG protein from AtaGenix, researchers established an EAE model and revealed how meningeal B cells drive MS relapse via MHC II-mediated antigen presentation, GM-CSF–dependent neutrophil recruitment, and endothelial activation. Local intracisternal anti-CD20 selectively depleted brain-resident B cells and reduced relapse severity. Published in Immunity (IF: 25.5). DOI: 10.1016/j.immuni.2025.06.016.

Patatin is a potato glycoprotein with emulsifying and antioxidant properties but limited by low expression and short-chain bias. With AtaGenix support, recombinant Patatin was expressed in Pichia pastoris (121 mg/L). The D286A mutant showed 3.2-fold enhanced activity toward long-chain pNP-C16, improved thermal stability, and maintained overall fold — demonstrating the first rational shift of Patatin's substrate preference toward industrial applications in functional lipids and green biocatalysis.

AtaGenix provides mammalian cell protein expression services (HEK293/CHO-S transient, CHO-K1/DG44 stable) for basic research, drug development, and diagnostic reagent production. 5,000+ projects delivered with native glycosylation, endotoxin <0.1 EU/mL, scalable from mL to 200 L+. ISO 9001 & ISO 13485 certified.

AtaGenix developed a custom phospho-specific antibody against human USP8 Ser718, enabling an Advanced Science (IF 14.3) study that identified USP8 as the core deubiquitinase governing MDA5 homeostasis. The AKT–USP8–MDA5 axis drives type I interferon signaling; inhibiting USP8 or AKT suppresses MDA5-induced autoimmunity in AGS mice and anti-MDA5-positive DM/SLE patient cells. DOI: 10.1002/advs.202503865.

A Cancer Communications study mapped the pAKT–pPCK1–pLDHA–SPRINGlac axis as a driver of ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma. Simvastatin disrupted mevalonate flux and restored therapy sensitivity in preclinical models. pAKT–pPCK1 emerged as a biomarker for patient stratification. AtaGenix provided custom phospho-specific antibodies (anti-pPCK1 Ser90, anti-pLDHA Thr248) validated for WB/IP/IHC. DOI: 10.1002/cac2.70036.

An Advanced Science study (IF 14.3) identified the PAD1–AKT2(R202)–CEBPβ axis as a driver of ovarian cancer stem-like cell stemness and cisplatin resistance. PAD1 citrullinates AKT2 at Arg202, maintaining phosphorylation site exposure and activating PI3K-AKT–CEBPβ signaling. PAD1 inhibition re-sensitizes cisplatin-resistant cells. AtaGenix provided a custom site-specific Cit202 antibody validated for co-IP and IHC across 66 clinical samples. DOI: 10.1002/advs.202501014.

A Nature Microbiology study revealed that the E2 enzyme in E2-CBASS regulates cGAS via ubiquitination mimicry, promoting poly-cGAS formation (4.2× increase) and cGAMP synthesis (2.3× boost) to confer anti-phage immunity. Cryo-EM resolved the cGAS-E2 covalent complex. AtaGenix provided a custom rabbit anti-cGAS polyclonal antibody that distinguished cGAS monomers (46 kDa), complexes (64 kDa), and poly-cGAS (>100 kDa) in Western blot. DOI: 10.1038/s41564-024-01684-z.

AtaGenix provides end-to-end bispecific antibody custom development supporting 15+ formats (BiTE, IgG-like, Fab-based, nanobody-based, multispecific). >90% project success rate using proprietary HEK293 and XtenCHO™ expression platforms. Full workflow from gene synthesis and vector construction to expression, purification, and QC (SDS-PAGE, SEC-HPLC, ELISA) in 5–6 weeks. Case studies include anti-EBV gH/gL and anti-GPC3×CD3E bispecific antibodies.

Comprehensive overview of therapeutic antibody derivatives: ADCs (10 FDA-approved, 80+ in clinical trials), ARCs (antibody-oligonucleotide conjugates), bispecific/multispecific antibodies (BiTE, CrossMab, Knobs-into-Holes), immunocytokines (IL-2, IL-12, TGF-β trap fusions), and antibody fragments (Fab, scFv, VHH nanobodies, DARPins). Covers mechanisms, approved products, and future directions including TCR-mimic antibodies for intracellular antigen targeting.

A Nature Communications study resolved the crystal structures of IdeS–IgG1 Fc and EndoS–IgG1 Fc complexes, revealing the molecular basis of substrate-specific recognition. IdeS cleaves the IgG hinge region; EndoS hydrolyzes the Fc N-glycan. Clinical applications include Guillain-Barré syndrome (37% independent walking at week 1), AAV gene therapy antibody clearance (Nature Medicine 2020), and anti-GBM renal disease (GOOD-IDES Phase II). AtaGenix offers recombinant IdeS protease (ATE00010, >95% purity, 40 U/μL).